与cuproptosis相关的PDHA1通过E2F1-PD-L1轴促进肉瘤进展和免疫疗法反应:一个多omics和临床验证研究
Haotian Qin1,2, Tiantian Qi1,2, Nan Yao3
1Department of Orthopedics, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
NPJ precision oncology
|March 6, 2026
概括
酸盐脱酶α1 (PDHA1) 通过将cuproptosis与PD-L1表达联系起来,驱动肉瘤的进展和免疫逃避. 向PDHA1可能会改善肉瘤患者的免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 免疫治疗是一种免疫疗法.
背景情况:
- 瘤是具有对免疫检查点阻塞 (ICB) 反应较差的侵袭性瘤.
- 确定新的治疗点对于改善肉瘤治疗结果至关重要.
- 了解瘤代谢和免疫逃避之间的相互作用是关键.
研究的目的:
- 为了确定肉瘤进展和免疫逃避的关键代谢驱动因素.
- 阐明PDHA1影响瘤微环境的机制.
- 评估PDHA1作为潜在的治疗标和肉瘤的生物标志物.
主要方法:
- 集成的多组学,功能性检测和临床数据分析.
- 免疫细胞的单细胞RNA测序.
- 在体外和体内实验,包括敲除,铜化和异种移植.
主要成果:
- 在肉瘤中,PDHA1过度表达,与预后不佳和免疫排除相关.
- 抑制PDHA1可以减少瘤的生长,入侵和PD-L1的表达.
- PDHA1通过E2F1通路调节PD-L1,铜化抑制了这一轴.
- 高的PDHA1与增加的瘤负担,改变的细胞存活标志物和减少的CD8+T细胞透有关.
结论:
- PDHA1是一个关键的代谢调节器,在肉瘤中协调免疫逃避.
- PDHA1-E2F1-PD-L1轴代表了一个新的治疗漏洞.
- PDHA1作为ICB响应的潜在生物标志物和肉瘤治疗的目标.
相关概念视频
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
PI3K/mTOR/AKT Signaling Pathway
6.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.0K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
Tumor Progression
7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Interactions Between Signaling Pathways
7.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K


